Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical 177Lu-DOTA-PSMA

The therapeutic efficacy of a Russian radiopharmaceutical177Lu-DOTA-PSMA was studiedin vivo using male BALB/c nu/nu (nude) mice with prostate carcinoma 22Rv1 xenografts by tumor growth inhibition criterion. The mean tumor volumes in mice treated with177Lu-DOTA-PSMA were significantly lower than in animals of the control group. There were no significant differences in the values of tumor growth inhibition between the groups of animals receiving 3.7 or 7.4 MBq of177Lu-DOTA-PSMA.
Source: Bulletin of Experimental Biology and Medicine - Category: Biology Source Type: research